Le bulletin du Programme National de Mentorat sur le VIH-Sida et du volet Hépatites 
  Numéro 66, mars 2011 
     
 Actualités 

Visioconférence - Développement d'un outil clinique pour mesurer la cognition chez les individus séropositifs
8 mars 2011 - Montréal

Visioconférence -
Post-CROI 2011

22 mars 2011 - Montréal

1er Symposium sur la prise en charge clinique des hépatites virales
29 avril 2011 - Montréal

7e Symposium de Québec sur les aspects cliniques de l'infection par le VIH
20 mai 2011 - Québec

 
Congrès à venir

CROI 2011
27 février au 2 mars 2011 - Boston, États-Unis

Journées québécoises VIH 2011
17 au 19 mars 2011 - Montréal

ACIIS-CANAC 2011
17 au 20 mars 2011- Montréal

9th European Workshop on HIV & Hepatitis
23 au 25 mars 2011- Paphos, Chypre

15th International Workshop on HIV Observational Databases
24 au 26 mars 2011- Prague, République Tchèque


Calendrier 2011-2012

 
 
 

1er Symposium sur la prise en charge clinique des hépatites virales
Le programme du symposium qui aura lieu le 29 avril 2011 est disponible. Vous pouvez vous inscrire dès maintenant.

Interim Guidance: Preexposure Prophylaxis for the Prevention of HIV Infection in Men Who Have Sex with Men – Centers for Disease Control and Prevention
Lignes directrices intérimaires des CDC américains sur la prophylaxie pré-exposition chez les HARSAH.

Conference on Retroviruses and Opportunistic Infections (CROI)
CROI, l’une des plus importantes conférences en VIH, a débuté dimanche à Boston. HIVandHepatitis.com vous propose une couverture de l’événement.

 
 Articles scientifiques  
 

Thérapie antirétrovirale

Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death
AIDS

The Evolution of Coreceptor Tropism in HIV-infected Patients Interrupting Suppressive Antiretroviral Therapy
Clinical Infectious Diseases

Atazanavir Pharmacokinetics With and Without Tenofovir during Pregnancy
JAIDS

First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial
The Lancet Infectious Diseases 

Résistance et mutations

The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?
AIDS Research and Therapy

Toxicité et interactions médicamenteuses

Comparative Effectiveness and Toxicity of Statins Among HIV-Infected Patients
Clinical Infectious Diseases

Markers of Bone Turnover Are Elevated in Patients With Antiretroviral Treatment Independent of the Substance Used
JAIDS

High Dose Atorvastatin Decreases Cellular Markers of Immune Activation without Affecting HIV-1 RNA Levels: Results of a Double-Blind Randomized Placebo Controlled Clinical Trial
The Journal of Infectious Diseases

Co-infections

Incident Hepatitis C Virus Infection among US HIV-Infected Men Enrolled in Clinical Trials
Clinical Infectious Diseases

HIV Infection and the Liver: The Importance of HCV-HIV Coinfection and Drug-Induced Liver Injury
Clinics in Liver Disease

Liver transplantation for hepatocellular carcinoma: The impact of human immunodeficiency virus infection
Hepatology

Infections opportunistes

Tuberculosis in Patients Receiving Antiretroviral Treatment: Incidence, Risk Factors, and Prevention Strategies
JAIDS

Autres maladies associées

HIV Mono-infection Is Associated With FIB-4 – A Noninvasive Index of Liver Fibrosis – in Women
Clinical Infectious Diseases

Influence of Adherent and Effective Antiretroviral Therapy Use on Human Papillomavirus Infection and Squamous Intraepithelial Lesions in Human Immunodeficiency Virus—Positive Women
The Journal of Infectious Diseases

Adhésion aux traitements

The Impact of the AIDS Drug Assistance Program (ADAP) on Use of Highly Active Antiretroviral and Antihypertensive Therapy Among HIV-Infected Women
JAIDS

Prévention

Interim Guidance: Preexposure Prophylaxis for the Prevention of HIV Infection in Men Who Have Sex with Men
MMWR (Lignes directrices intérimaires)

Autres

Maternal HIV Infection and Antibody Responses Against Vaccine-Preventable Diseases in Uninfected Infants
JAMA

A Therapeutic Dendritic Cell-Based Vaccine for HIV-1 Infection
The Journal of Infectious Diseases

Transcriptional Profiling of CD4 T Cells Identifies Distinct Subgroups of HIV-1 Elite Controllers
Journal of Virology

A Low T Regulatory Cell Response May Contribute to Both Viral Control and Generalized Immune Activation in HIV Controllers
PLoS ONE

Hépatites

Telaprevir Is Effective Given Every 8 or 12 Hours With Ribavirin and Peginterferon Alfa-2a or -2b to Patients With Chronic Hepatitis C
Gastroenterology

Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b
Journal of Hepatology

Communiqué de presse

Tibotec Starts Global Phase 3 Clinical Trials Studying TMC435 In Adults With Chronic Genotype 1 HCV
Tibotec

Kaletra (lopinavir/ritonavir) Oral Solution label changes related to toxicity in preterm neonates
U. S. Food and Drug Administration

Reyataz (atazanavir) label revised, adding dosing recommendations for pregnancy and postpartum period
U. S. Food and Drug Administration

Shionogi-ViiV Healthcare Starts Phase III Trial for "572-Trii" Fixed-Dose Combination HIV Therapy
ViiV Healthcare

  

 
  Communiquer avec nous
 


Programme National de Mentorat sur le VIH-SIDA
(PNMVS)
300, rue Sainte-Catherine Est, 3e étage
Montréal, Québec, H2X 1L7
Téléphone : 514.282.9606
Télécopieur : 514.282.9607
Site web : www.pnmvs.org 

Pour toutes questions concernant notre centre de documentation contacter:
Louis-Philippe Vézina, documentaliste
Courriel : doc@pnmvs.org

Pour toutes questions concernant le membership, les événements et les activités du PNMVS contacter:
Claude Pichette, adjoint à la coordination
Courriel : info@pnmvs.org
 

 
  © 2011 PNMVS